The Danish pharma company, Novo Nordisk is planning to introduce its new diabetic insulin called 'GLP1 analogue insulin', which would perform intermediate action, in the Indian and other markets soon.

Talking to Pharmabiz, Jesper Høiland, senior vice-president, Novo Nordisk, said that the company had been engaged in developing the improved form of human insulin. It already has similar type of insulin called Levimir in the markets, but with some limited effects. "Now the new insulin is under phase III clinical trial and as soon as it is over, we want to introduce it in the Indian as well as overseas markets", added Jesper.

He revealed that this modern insulin or insulin analogue GLP1, which was genetically modified, was made in the laboratory. "The new insulin GLP1 will prevent nocturnal hypoglycaemia, with no weight gain benefit as company's other product Levimir does, but with some advanced effect and benefits for the diabetic patients", stated Jesper.

It may be noted that there are mainly three types of insulin available in the market for diabetic patients like short action, long action and intermediate action. The company, Nova Nordisk, is concentrating only on the intermediate actions insulin as it is more comfortable for a diabetic patient.

In this area, the company has three brands -- Nova Mix, Nova Rapid and Levimir insulins. Out of these, Levimer is of intermediate action which shows its effect for 24 hours within the body. The company official also claimed that their main driver for their business was modern insulin.